The OPHT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OPHT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OPHT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OPHT Detailed Price Forecast - CNN Money||View OPHT Detailed Summary - Google Finance|
|View OPHT Detailed Summary - Yahoo! Finance||View OPHT Stock Research & Analysis - Zacks.com|
|View OPHT Trends & Analysis - Trade-Ideas||View OPHT Major Holders - Barrons|
|View OPHT Call Transcripts - NASDAQ||View OPHT Breaking News & Analysis - Seeking Alpha|
|View OPHT Annual Report - CompanySpotlight.com||View OPHT OTC Short Report - OTCShortReport.com|
|View OPHT Fundamentals - TradeKing||View OPHT SEC Filings - Bar Chart|
|View Historical Prices for OPHT - The WSJ||View Performance/Total Return for OPHT - Morningstar|
|View the Analyst Estimates for OPHT - MarketWatch||View the Earnings History for OPHT - CNBC|
|View the OPHT Earnings - StockMarketWatch||View OPHT Buy or Sell Recommendations - MacroAxis|
|View the OPHT Bullish Patterns - American Bulls||View OPHT Short Pain Metrics - ShortPainBot.com|
|View OPHT Stock Mentions - StockTwits||View OPHT Stock Mentions - PennyStockTweets|
|View OPHT Stock Mentions - Twitter||View OPHT Investment Forum News - Investor Hub|
|View OPHT Stock Mentions - Yahoo! Message Board||View OPHT Stock Mentions - Seeking Alpha|
|View Insider Transactions for OPHT - SECform4.com||View Insider Transactions for OPHT - Insider Cow|
|View OPHT Major Holdings Summary - CNBC||View Insider Disclosure for OPHT - OTC Markets|
|View Insider Transactions for OPHT - Yahoo! Finance||View Institutional Holdings for OPHT - NASDAQ|
|View OPHT Stock Insight & Charts - FinViz.com||View OPHT Investment Charts - StockCharts.com|
|View OPHT Stock Overview & Charts - BarChart||View OPHT User Generated Charts - Trading View|
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
Posted on Monday November 12, 2018
Ophthotech Corporation (OPHT) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD and was the first in human trial assessing the safety of Zimura 4mg dose in combination with Lucentis® (ranibizumab) 0.5mg, an anti-vascular endothelial growth factor (anti-VEGF). Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with anti-VEGF drugs.
Report: Exploring Fundamental Drivers Behind Coeur Mining, Spectra Energy Partners, LP, Quaker Chemical, Ophthotech, Iron Mountain, and Apollo Global Management — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Tuesday November 06, 2018
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Edited Transcript of OPHT earnings conference call or presentation 31-Oct-18 12:00pm GMT
Posted on Friday November 02, 2018
Q3 2018 Ophthotech Corp Earnings Call
Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
Posted on Thursday November 01, 2018
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.